Compare OSK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSK | CORT |
|---|---|---|
| Founded | 1917 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.6B |
| IPO Year | N/A | N/A |
| Metric | OSK | CORT |
|---|---|---|
| Price | $154.10 | $34.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $152.67 | $111.00 |
| AVG Volume (30 Days) | 640.9K | ★ 2.9M |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.25 | 0.87 |
| Revenue | ★ $10,331,600,000.00 | $741,172,000.00 |
| Revenue This Year | N/A | $21.70 |
| Revenue Next Year | $5.72 | $30.13 |
| P/E Ratio | ★ $14.97 | $40.52 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $76.82 | $32.99 |
| 52 Week High | $155.71 | $117.33 |
| Indicator | OSK | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 73.10 | 20.86 |
| Support Level | $125.51 | $34.28 |
| Resistance Level | $155.71 | $37.48 |
| Average True Range (ATR) | 4.30 | 2.89 |
| MACD | 1.69 | -1.12 |
| Stochastic Oscillator | 92.17 | 4.15 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (49% of revenue), Vocational (31%), and Transport (20%) on 2024 revenue of $10.7 billion.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.